Eventide Asset Management’s Keros Therapeutics KROS Stock Holding History

Eventide Asset Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-380,000	Closed	-$6.02M	–	242
2024 Q4	$6.02M	Hold	380,000	–	–	0.11%	151
2024 Q3	$22.1M	Sell	380,000 -119,208	-24%	-$5.89M	0.38%	83
2024 Q2	$22.8M	Sell	499,208 -180,792	-27%	-$9.71M	0.39%	82
2024 Q1	$45M	Buy	680,000 +100,000	+17%	+$5.93M	0.71%	52
2023 Q4	$23.1M	Hold	580,000	–	–	0.38%	77
2023 Q3	$18.5M	Hold	580,000	–	–	0.33%	89
2023 Q2	$23.3M	Buy	580,000 +280,000	+93%	+$12.3M	0.39%	78
2023 Q1	$12.8M	Buy	+300,000	New	+$15.2M	0.24%	112
2021 Q3	–	Sell	-427,414	Closed	-$18.2M	–	156
2021 Q2	$18.2M	Hold	427,414	–	–	0.24%	99
2021 Q1	$26.3M	Buy	427,414 +81,414	+24%	+$5.16M	0.39%	81
2020 Q4	$24.4M	Buy	+346,000	New	+$21.8M	0.37%	81

Other funds holding KROS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Eventide Asset Management's KROS Position: Q1 2025 in Review

Eventide Asset Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 380,000 shares — an estimated $6.02M sold.

Eventide Asset Management first reported a position in KROS in Q4 2020 and held it in 11 quarters. The position peaked at $45M in Q1 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

Eventide Asset Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
Eventide Asset Management sold 380,000 Keros Therapeutics shares in Q1 2025, an estimated $6.02M.
Eventide Asset Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 11 quarters.
Eventide Asset Management's Keros Therapeutics position peaked at $45M in Q1 2024.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Eventide Asset Management's 13F filing for Q1 2025, filed 15 May 2025.